恒瑞重返第一,百利天恒首登,六成公司“新晋”,谁在定义药企竞争力?2025年竞争力20强揭榜

动脉网
Yesterday

医药行业正从“增量时代”过渡到“存量竞争”,韧性成为药企新竞争力,涵盖修复力、适应力与再生力。这种能力不仅体现在账面业绩稳定,更在于结构上的自我调整,如产品结构切换、商业模型重新配置及组织管理弹性。2024年,医药行业持续调整,表现不振,但仍有众多优秀公司逆周期增长。2025年中国医药上市公司竞争力20强展示了具备“穿越周期”潜力的药企,它们主动求变,承受压力并快速“修复”。面对行业结构性拐点,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10